David Birch, Ph.D.
Director, Rose-Silverthorne Retinal Degenerations Laboratory
Ph. D., University of California, Santa Barbara, 1978
Office: 214-363-3911 ext.105
Genetic eye diseases, Macular degeneration, Electrophysiology, Visual function testing
Birch DG and Anderson JL. Standardized full-field ERGs: normal values and their variation with age. Arch Ophthal, 1992;110:1571-1576.
Birch DG, Hood DC, Nusinowitz S, and Pepperberg DR. Abnormal activation and inactivation of rod transduction in patients with autosomal dominant retinitis pigmentosa and the pro-23-his mutation. Invest Ophthalmol Vis Sci, 1995; 36:1603-1614.
Birch DG, Anderson JL, and Fish GE. Yearly rates of rod and cone functional loss in retinitis pigmentosa and cone-rod degeneration. Ophthalmol, 1999; 106:258-268.
Birch DG. Surrogate electroretinographic markers for assessing therapeutic efficacy in the retina. Exp Rev Mol Diag. 2004; 4: 693-703. PMID: 15347262.
Birch DG, Liang FQ. Age-related macular degeneration: A target for nano-technology derived medicines. International J. Nanomedicine. 2007; 2:1-13. PMID: 17722514.
Hood DC, Lazow MA, Locke KG, Greenstein VC, Birch DG. The transition zone between healthy and diseased retina in patients with retinitis pigmentosa (RP). Invest. Ophthalmol Vis Sci, 2011; 52: 101-108. Aug 20 (Epub ahead of print] PMID: 20720228.
Birch DG, Wen Y, Locke KI, Hood DC. Rod sensitivity, cone sensitivity and photoreceptor layer thickness in retinal degenerative diseases. Invest Ophthalmol Vis Sci, 2011; 52(10): 7141-7. Sept 9, 2011 [Epub ahead of print] PMID: 21810977.
Wen YE, Klein M, Hood DC, Birch DG. Relationships among multifocal electroretinogram amplitude, visual field sensitivity, and SD-OCT receptor layer thickness in patients with retinitis pigmentosa. Invest Ophthalmol Vis Sci; Jan 12, 2012 [Epub ahead of print].
Dr. David Birch
Retina Foundation of the Southwest
9600 N. Central Expressway, Suite 200
Dallas, TX 75231
Related ArticlesThe Phyllis G. & William B. Snyder Legacy Society National Eye Institute Awards $949,804 for a 5-Year Study of RP 9th Annual David R. Stager Sr., M.D. Lecture Retina Foundation to Conduct First Optogenetics Gene Therapy Clinical Trial Retina Foundation Completes $3.7M Capital Campaign